TABLE 1.
Baseline characteristics
| Variable | Value |
|---|---|
| Number of patients | 111 (100%) |
| Age | 50.58 ± 8.74 |
| Females | 88/111 (79.28%) |
| Menopause | 45/88 (51.14%) |
| Age of menopause | 48.57 ± 3.42 |
| Aura | 28/111 (25.23%) |
| Allodynia | 27/111 (24.11%) |
| Migraine duration | 33.58 ± 11.52 |
| CM duration | 14.53 ± 10.78 |
| Medication overuse duration | 8.79 ± 8.05 |
| Overused analgesics | |
| Triptans | 97/111 (87.39%) |
| NSAIDs | 44/111 (39.64%) |
| Combinations | 13/111 (11.71%) |
| Number of preventive treatment failed | 6.3 ± 2.21 |
| Failed topiramate | 83/111 (74.77%) |
| Failed BT‐A | 39/111 (35.14%) |
| Comorbidities | 99/111 (89.19%) |
| Anxiety | 35/111 (31.53%) |
| Depression | 40/111 (36.04%) |
| Fibromyalgia | 13/111 (11.71%) |
| Erenumab in add‐on | 61/111 (54.89%) |
| Detoxification | 20/111 (18.02%) |
| NHD | 23.16 ± 6.69 |
| AC | 40.41 ± 34.76 |
| NDM | 23.08 ± 6.88 |
| NRS | 8.16 ± 0.87 |
| HIT‐6 | 65.5 ± 6.63 |
| MIDAS | 69.49 ± 20.08 |
Abbreviations: AC, analgesic consumption; BT‐A, onabotulinumtoxinA; CM, chronic migraine; HIT‐6, 6‐items headache impact test; NDM, number of days on medication; NHD, number of headache days; NRS, numeric rating scale; NSAIDs, nonsteroidal anti‐inflammatory drugs; MIDAS, migraine disability assessment.